ATAI Life Sciences N.V. Aktie News

AtaiBeckley NV (NASDAQ:ATAI, ETR:9VC) reported continued clinical and operational progress during the third quarter of 2025, advancing multiple programs targeting treatment-resistant depression (TRD) and other mental health conditions. During the quarter, the company's lead candidate BPL-003, a mebufotenin (5-MeO-DMT) benzoate nasal spray, was granted Breakthrough Therapy designation by the US ...

AtaiBeckley NV (NASDAQ:ATAI, ETR:9VC) is gaining analyst attention after Phase 2b results for its investigational therapy BPL-003 demonstrated rapid, meaningful, and durable antidepressant effects in treatment-resistant depression (TRD), reinforcing its potential as a differentiated psychedelic therapy. Jefferies highlighted that the data could influence dosing strategies and commercial positio...

Atai Beckley N.V. ( ATAI ) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant Depression November 10, 2025 8:00 AM EST Company Participants Ashleigh Barreto Srinivas Rao - Co-Founder, CEO & Executive Director Kevin Craig - Chief Medical Officer Robert Conley - Chief Research & Development Officer Conference Call Participants Lin Tsai - Jefferies LLC, Research ...

AtaiBeckley NV (NASDAQ:ATAI, ETR:9VC) has unveiled positive topline results from the open-label extension (OLE) study of its Phase 2b clinical trial evaluating BPL-003 in patients with treatment-resistant depression (TRD). The company said that a 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 0.3 mg, 8 mg, or 12 mg dose produced additional rap...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that its previously annoucned strategic combination with Beckley Psytech has been completed, forming a new clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders called AtaiBeckley. Atai Life Sciences shareholders approved the transaction and a corporate redomiciliation to Delaware at an Extraordi...

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced the completion of a $149.5 million public offering of approximately 27 million common shares, including the full exercise of underwriters' option to purchase an additional 3.6 million shares at $5.48 per share. The financing included participation from both new and existing investors, such as Janus Henderson Investors, Foresite Capital, Deep T...

Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003 Cash, cash equivalents, short-term investments and other liquid assets expected to fund operations into 2029, beyond anticipated top-line results from the first Phase 3 clinical trial of BPL-003

ATAI's main value driver is BPL-003. This candidate showed rapid and durable TRD benefits in its Phase 2b trials. BPL-003's 8 mg dose seemed to be ideal, which is why ATAI is going ahead with a Phase 3 with this dosing by Q2 2026. ATAI's broader pipeline includes VLS-01 DMT buccal film, EMP-01 R-MDMA for SAD, and other early-stage non-hallucinogenic 5-HT2A candidates.